Pharmaceuticals News

Entrada Therapeutics announces that an independent DMC recommends initiation of Cohort 3 at the top dose of 18 mg/kg in the ELEVATE-44-201 study.

Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer

FDA’s Rare Disease Evidence Principles (RDEP) process aims to provide greater speed and predictability in the review of therapies for rare diseases with significant unmet medical need Acceptance...

Entrada Therapeutics announces positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45.

Arexera Therapeutics, Formerly Atalanta Therapeutics, Unveils New Corporate Identity and Advances Huntington's Disease Franchise

Elion has an exclusive global license to a novel inhaled polyene antifungal to prevent fungal infections in patients receiving immunosuppressive therapies.

New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors Zolucatetide directly inhibits...

Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually...

Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapiesExpands access...

EMA grants Orphan Drug Designation to investigational QRX003 for Peeling Skin Syndrome, its eighth regulatory designation across two indications.